Mölnlycke to present new evidence supporting reduced incidence of Surgical Site Infections associated with C-Sections

Norcross, GA. March 23, 2018- Mölnlycke’s commitment to advancing performance in wound care and surgical solutions is highlighted by the presentation of new evidence to benefit caregivers and patients at this year’s AORN, which will be held at Morial Convention Center, in New Orleans, March 24-28. Focused on reduction of Surgical Site Infections (SSI) on C-Sections, two new studies support an up to 10-fold reduction in SSIs through utilization of Mepilex Border Post-Op antimicrobial dressings as part of surgical protocol. Mölnlycke will make this evidence and related materials available in their exhibit at Booth 1623.

Mölnlycke will also showcase Mepilex® Border Sacrum and Heel and Z-FloTM Fluidized positioners for Pressure Ulcer Prevention, in addition to its trusted line up of prevention to post-acute solutions.

“Continued caregiver and patient understanding is important to us and central to what we call having ‘Customer at Heart’. Combined with our gained expertise and advanced technologies, we’ve developed a portfolio of SSI bundle solutions for perioperative care. Mölnlycke truly believes that together we can make a difference. Everyone involved - the patient, health care provider, the care facility and our healthcare system overall- benefits when we are able to work together to reduce infection rates,” says Al Concemi, Vice President Surgical Marketing.

Why SSI matters

Surgical site infections are a leading hospital-acquired condition and cause for readmission. If a patient acquires an SSI, their hospital stay will be extended, on average 9.7 days, and an estimated $20,000 in increased healthcare costs [1] will be incurred. Healthcare providers, more than ever, are seeking improved solutions that will help achieve the best patient care outcomes and provide value all around.

“Our solutions are true to Mölnlycke’s purpose of advance performance in healthcare across the world. When looking at the patient and caregiver experience, we aspire to equip both with solutions to achieve the best outcomes. This is why we care about prevention of Surgical Site Infections. Simply put, we know they are a significant issue impacting patient care and increasing health care costs and we want to be the best partner in making a positive difference in this space,” adds Randy Schwartz, Vice President Wound Care Marketing.

The Mölnlycke Solution Line-Up

Mölnlycke offers many solutions that provide a solid foundation for a systematic preventive SSI combined solution. These include, Biogel® technically advanced surgical gloves, HIBICLENS® antiseptic/antimicrobial skin cleanser and Mepilex® Border Post-Op and antimicrobial dressings.

Mepilex® Border Post-Op Dressings

Mepilex® Border Post-Op dressings’ new flex-cut pad stretches in all directions, conforming to the body even as it moves, which supports early patient mobilization. [2,3] Its Safetac® technology is clinically proven to minimize dressing-related skin damage and helps reduce pain during dressing changes.[4] The Mepilex® Border Post-op dressings also feature a shower-proof seal that supports longer wear time and low frequency of dressing changes.[5]

Available as a standard or antimicrobial dressing, Mepilex® Border Post-Op Ag contains highly soluble silver that starts inactivating pathogenic bacteria in the dressing within 30 minutes. In vitro testing shows that the dressing continues to inactivate 99.99% of common microbial threats for 7 days.[6-8]

Biogel® technically advanced surgical gloves

Mölnlycke now offers thinner, synthetic surgical glove alternatives to facilitate the transition from single-gloving.

According to the Cochrane Review, double-gloving has been recognized as the most effective method for lowering the frequency of leakage, reducing the number of glove perforations by 71%.[9] Glove perforation introduces risk of SSIs that can be mitigated with glove changes and double-gloving.

The Biogel® PI Micro Indicator® Underglove, when, combined with the Biogel® PI Micro overglove, creates the proprietary Biogel® Puncture Indication System® that quickly alerts the user to a glove puncture or breach with a visual cue. 85% of O.R. staff who tested the product in a user evaluation preferred the new glove combination compared to their current surgical gloves [10]. 

HIBICLENS®

Trusted for over 40 years to prevent infection, HIBICLENS® is a gentle 4% CHG antiseptic skin cleanser commonly used for preoperative showering in SSI reduction combined solutions. Our foaming dispenser helps make HIBICLENS® easy to use and provides patients with visual evidence that encourages better coverage. With our gentle formulation, easy to use product, and library of patient education, Mölnlycke is dedicated to helping patients remain compliant with vital infection prevention protocols.

Mepilex® Border Sacrum and Heel Pressure Ulcer Prevention Dressings

The Mepilex® Border with Deep Defense™ technology was designed to significantly reduce factors that cause pressure ulcers, including friction, shear, pressure and microclimate, and its effectiveness has been demonstrated through four randomized controlled clinical trials and several systematic reviews. [11]

No other dressing on the market exhibits these same properties – or the same proven clinical results – in pressure injury prevention. Proprietary Mepilex® Border is the only 5-layer foam dressing for which over 70 evidence pieces exist to support its effectiveness in preventing pressure ulcers.11 The cost-effectiveness of Mepilex Border has been studied in the largest economic study of prophylactic dressings published to date, demonstrating significant return on investment in less than one year and up to $77 reduction in spending on pressure injury treatment from $120/patient to $43/patient.[12]

Z- FloTM Fluidized Positioners

Mölnlycke also offers unique fluidized positioners that help achieve pressure redistribution as well as natural body alignment. The right positioner can help deliver safe, secure, maintainable repositioning and protect at-risk anatomical sites.

# # #

References: 1. Ban, Kristen A. et al. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. Journal of the American College of Surgeons , Volume 224 , Issue 1 , 59 - 74. 2. Johansson C et al. Preventing post-operative blisters following hip and knee arthroplasty. Wounds International, 2012. 3. Bredow, J. et al. Randomized clinical trial to evaluate the performance of a flexible self-adherent absorbent dressing coated with a soft silicone layer compared to a standard wound dressing after hip, knee or spinal surgery in comparison to standard wound dressing. Poster presentation at 5th Congress of WUWHS, Florence, Italy 2016. 4. Dykes, P.J., et al. Effects of adhesive dressings on the stratum corneum of skin. J Wound Care 2001; 10: 2, 7-10. 5. Feili, F et al. Fluid Handling Properties of Antimicrobial Post-Operative Wound Dressings. Data on file. 6. Data on file. Laboratory test 20151026-005. 7. Data on file. Laboratory test 20151109-002. 8. Data on file. Laboratory test 20151110-007 9. Mischke C, Veerbeck JH, Saarto A, Lavoie M-C, Pahwa M, Ijaz S, Cochrane Database of Systematic Reviews 2014;(3):CD009573. 10 Data on file, MHC.11. GMCS/2017/102/V4. Results of literature search for peer-reviewed journal articles and conference posters relating to dressings for pressure injury prevention (September 2017). Data on file. 12. Padula WV. Effectiveness and value of prophylactic 5-layer foam sacral dressings to prevent hospital-acquired pressure injuries in acute care hospitals. An observational cohort study. Journal of Wound Ostomy and Continence Nursing. 2017. 44(5):413-419.

###

The Mölnlycke Health Care, Biogel, HIBICLENS, Mepilex, Safetac and Indicator trademarks, names and logo types are registered globally to one or more of the Mölnlycke Health Care Group of Companies. Z- Flo is a trademark in the United States and other countries of EdiZONE, LLC of Alpine, Utah, USA. Distributed by Mölnlycke Health Care US, LLC, Norcross, Georgia 30092. © 2017 Mölnlycke Health Care AB. All rights reserved. 1-800-882- 4582.

For media inquiries, contact:

Anabell Iglesias

Communications at Mölnlycke US

anabell.iglesias@molnlycke.com

www.molnlycke.us

Headquartered in Gothenburg, Sweden, Mölnlycke Health Care is a provider of high-quality healthcare solutions for customers, healthcare professionals and patients worldwide. We develop and bring to market innovative wound care and surgical solutions along the entire continuum of care – from prevention to post-acute settings. Our value-based solutions provide reduction of healthcare acquired conditions supported by scientific, clinical, and health economic evidence. Since our beginning in 1846, we’ve grown into a global company and customers use our solutions in almost 100 countries. To learn more about our story, brands, and what we care about, visit www.molnlycke.us

Tags:

About Us

Mölnlycke is a world-leading medical solutions company. We design and supply solutions to enhance performance at every point of care – from the hospital to the home. We specialise in solutions for managing wounds, improving surgical safety and efficiency, and preventing pressure ulcers. Our products are available in approximately 100 countries worldwide. Mölnlycke was founded in 1849. Our headquarters are in Gothenburg, Sweden and we employ around 7,500 people. Since 2007, we belong to Investor AB, the leading owner of Nordic-based international companies.

Subscribe

Documents & Links

Quick facts

Mölnlycke will make available at AORN two new studies that support an up to 10-fold reduction in SSIs through utilization of Mepilex Border Post-Op antimicrobial dressings as part of surgical protocol.
Tweet this
Mölnlycke will also showcase Mepilex® Border Sacrum and Heel and Z-FloTM Fluidized positioners for Pressure Ulcer Prevention, in addition to its trusted line up of prevention to post-acute solutions.
Tweet this

Quotes

Our solutions are true to Mölnlycke’s purpose of advance performance in healthcare across the world. When looking at the patient and caregiver experience, we aspire to equip both with solutions to achieve the best outcomes. This is why we care about prevention of Surgical Site Infections. Simply put, we know they are a significant issue impacting patient care and increasing health care costs and we want to be the best partner in making a positive difference in this space.
Randy Schwartz, Vice President Wound Care Marketing US
Continued caregiver and patient understanding is important to us and central to what we call having ‘Customer at Heart’. Combined with our gained expertise and advanced technologies, we’ve developed a portfolio of SSI bundle solutions for perioperative care. Mölnlycke truly believes that together we can make a difference. Everyone involved - the patient, health care provider, the care facility and our healthcare system overall- benefits when we are able to work together to reduce infection rates.
Al Concemi, Vice President Surgical Marketing US